NCT02194426 - First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 20, 2018

Study Completion Date

February 20, 2018

Conditions

Neoplasms

Interventions

DRUG

MP0250

Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.

Trial Locations (4)

Study Site Barcelona, Barcelona

Study Site St. Gallen, Sankt Gallen

Study Site Cambridge, Cambridge

Study Site Oxford, Oxford